WASHINGTON, DC, Oct. 3 – Pluvita, a drug-discovery and development company, has acquired a majority stake in Diogenics, a privately held genomic firm, the companies said on Wednesday.
The acquisition, for an undisclosed amount, was designed to allow Pluvita to combine its bioinformatics, information management, and clinical databases with Diogenics’ wet-lab capabilities, model systems, and intellectual property assets, Pluvita said in a statement.
“This is a key validation from a research organization of Pluvita’s unique model to accelerate the drug discovery and development process,” the company said before the start of the Biotechnology Industry Organization venture capital forum here this week, where it is participating. “The Diogenics acquisition is a collaborative partnership and serves as proof-of-principle of our unique approach to target and lead identification and optimization,” Pluvita CEO Gary J. Kurtzman added in a statement.
Diogenics, of Irvine, Calif., identifies and validates clinically relevant gene and protein targets in steroid hormone-responsive diseases, including prostate cancer, BPH, breast cancer, ovarian cancer, and other reproductive diseases, according to Pluvita.
Beside Diogenics’ wet lab capabilities and intellectual property assets, Bethesda, Md.-based Pluvita will acquire a scientific team experienced in molecular biology, microarray technology, protein expression, immunology, reproductive biology, vaccine delivery, functional genomics, proteomics, structural biology, and bioinformatics, Pluvita said.
The Diogenics acquisition is the first in a series of strategic relationships Pluvita plans over the next year, according to Pluvita.